EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy

Rebecca F Slykerman, Naomi Davies, Klara Vlckova, Kenneth J O'Riordan, Shalome A Bassett, James Dekker, Harriët Schellekens, Niall P Hyland, Gerard Clarke iD, Elaine Patterson

Microbial Biotechnology · 2025-01 · 18 (1)

DOI: 10.1111/1751-7915.70079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 15.01.2025. Verfasst von Rebecca F Slykerman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics, Brain, Brain-Gut Axis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonterra Co-Operative Group, Science Foundation Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancing microbiome–gut–brain axis science requires systematic, rational and translational approaches to bridge the critical knowledge gaps currently preventing full exploitation of the gut microbiome as a tractable therapeutic target for gastrointestinal, mental and brain health. Current research is still marked by many open questions that undermine widespread application to humans. For example, the lack of mechanistic understanding of probiotic effects means it remains unclear why even apparently closely related strains exhibit different effects in vivo. For the therapeutic application of live microbial psychobiotics, consensus on their application as adjunct treatments to conventional neuromodulators, use in unmedicated populations or in at‐risk cohorts with sub‐clinical symptomatology is warranted. This missing information on both sides of the therapeutic equation when treating central nervous system (CNS) conditions makes psychobiotic research challenging, especially when compared to other pharmaceutical or functional food approaches. Expediting the transition from positive preclinical data to proven benefits in humans includes interpreting the promises and pitfalls of animal behavioural assays, as well as navigating mechanism‐informed decision making to select the right microbe(s) for the job. In this review, we consider how these decisions can be supported in light of information accrued from a range of clinical studies across healthy, at‐risk and pathological study populations, where specific strains have been evaluated in the context of gastrointestinal physiology, brain function and behaviour. Examples of successful, partial and unsuccessful translation from bench to bedside are considered. We also discuss the developments in in silico analyses that have enhanced our understanding of the gut microbiome and that have moved research towards pinpointing the host–microbe interactions most important for optimal gut–brain axis function. Combining this information with knowledge from functional assays across in vitro and ex vivo domains and incorporating model organisms can prime the discovery pipelines with the most promising and rationally selected psychobiotic candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeProbioticsBrainBrain-Gut AxisHumansAnimalsGastrointestinal Tract

Stichwörter der Autor:innen

GPCRbehaviourgut‐brain axismicrobiomeprobioticpsychobioticshort chain fatty acidstryptophan

Autor:innen und Institutionen

  • Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.
  • Fonterra Microbiome Research Centre, University College Cork, Cork, Ireland.
  • APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Fonterra Research and Development Centre, Palmerston North, New Zealand.
  • Riddet Institute, Massey University, Palmerston North, New Zealand.
  • Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.

ORCID-Profile: Gerard Clarke

Förderung

  • Fonterra Co-Operative Group
  • Science Foundation Ireland

Zitieren

APA

Slykerman, R. F., Davies, N., Vlckova, K., O'Riordan, K. J., Bassett, S. A., Dekker, J., Schellekens, H., Hyland, N. P., Clarke, G., & Patterson, E. (2025). Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy. Microbial Biotechnology, 18(1). https://doi.org/10.1111/1751-7915.70079

Vancouver

Slykerman RF, Davies N, Vlckova K, O'Riordan KJ, Bassett SA, Dekker J, et al. Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy. Microbial Biotechnology. 2025;18(1). doi:10.1111/1751-7915.70079

BibTeX
@article{Slykerman2025,
  author = {Slykerman, Rebecca F and Davies, Naomi and Vlckova, Klara and O'Riordan, Kenneth J and Bassett, Shalome A and Dekker, James and Schellekens, Harriët and Hyland, Niall P and Clarke, Gerard and Patterson, Elaine},
  title = {Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy},
  journal = {Microbial Biotechnology},
  year = {2025},
  volume = {18},
  number = {1},
  doi = {10.1111/1751-7915.70079}
}
Kostenlos starten →